Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating Expenses:
Research and development expenses	$ 12,249	$ 13,583
Selling, general and administrative expenses	11,577	11,655
Loss from Operations	(23,826)	(25,238)
Other Income:
Realized gain from sales of trading securities	1,640	1,074
Unrealized (loss) gain from trading securities	(22)	468
Interest income	389	180
Total Other Income	2,007	1,722
Net Loss	$ (21,819)	$ (23,516)
Net Loss Per Basic Common Share	$ (1.27)	$ (1.91)
Net Loss Per Diluted Common Share	$ (1.27)	$ (1.91)
Weighted Average Number of Common Shares Outstanding:
Basic	17,142	12,301
Diluted	17,142	12,301